Pertuzumab;Pertuzumab [INN]; 2C4; Omnitarg; Omnitarg, 2C4; UNII-K16AIQ8CTM; rhuMAb 2C4; Immunoglobulin G1, anti-(human v (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer
pH value
Corresponds to reference standard： PASS
Non-reduced CE-SDS
98.5%
SEC-HPLC
99.1%
Isoelectric Point
Corresponds to reference standard
Bacterial Endotoxins Test
＜1 EU/ml
Residual Proteins of Host Cell
Exogenous Residual DNA
＜1 pg/mg
Residual protein A
＜1 ng/mg
Biological Activity
Compared with standard, the range ofbiological activity is 103%
Osmolality
Corresponds to reference standard: PASS
Peptide mapping
Corresponds to reference standard: PASS
N-terminal sequence
Corresponds to reference standard:PASS
Biological activity
Description
CAS NO.：380610-27-5 Product Name：Pertuzumab Synonyms：Pertuzumab;Pertuzumab [INN]; 2C4; Omnitarg; Omnitarg, 2C4; UNII-K16AIQ8CTM; rhuMAb 2C4; Immunoglobulin G1, anti-(human v (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer EINEC: Molecular Formula： Molecular Weight：
Target:
HER2
In Vivo
In Calu-3 NSCLC xenografts, monotherapy with pertuzumab or trastuzumab is able to significantly inhibit tumor growth, with treatment-to-control ratios (TCR) of 0.23 and 0.27, respectively. The combination of trastuzumab and pertuzumab produces a dramatically enhanced antitumor activity compared with single-agent treatments (TCR 0.05, resulting in tumor regression and, in 3 of 10 animals, complete tumor remission). Treatment of KPL-4 breast cancer xenografts with either trastuzumab or pertuzumab inhibits tumor growth with TCRs of 0.67 and 0.65, respectively. Pertuzumab maintains antitumor activity after progression on trastuzumab[2].
In Vitro
Trastuzumab and Pertuzumab are highly synergistic inhibitors of BT474 breast cancer cell survival. The combination of trastuzumab and Pertuzumab mediates a loss of up to 60% of cells at doses in which individual drugs do not alter cell survival. The combination of trastuzumab and Pertuzumab reduces the percentage of proliferating (S-phase) cells by more than 2-fold. A combination of trastuzumab and Pertuzumab inhibits cell proliferation and survival to a greater degree than does either agent alone[1].
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Nahta R, et al. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survivalof breast cancer cells. Cancer Res. 2004 Apr 1;64(7):2343-6.
[2]. Scheuer W, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009 Dec 15;69(24):9330-6.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
